Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local trafermin (bFGF, REGROTH) for delayed socket healing in high-risk MRONJ patients
jRCTs051260109Recruiting
- Sponsor
- Japan Society for the Promotion of Science
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of regorafenib in medication-related osteonecrosis of the jaw (MRONJ) and Post-extraction socket healing impairment, sponsored by Japan Society for the Promotion of Science. Primary endpoint: Delayed socket healing at 8 weeks. Started Aug 2026; status: recruiting.
02
Drugs
regorafenib
03
Conditions
medication-related osteonecrosis of the jaw (MRONJ)Post-extraction socket healing impairment
Beyond the preview
Go deeper on jRCTs051260109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260109.